combination therapy with SGLT2i and GLP-1RA is recommended for this same population when glycemic targets have not been met with monotherapy [6, 7]
While the medication may still be safe to take in higher doses, it has not been tested or proven at those higher doses, or if it has been tested, the rate of side effects (especially serious side effects) has been determined to be too high to be safe
Growth hormone category: CJC-1295, ipamorelin, and other growth hormone releasing peptides round out the product selection
However, their clinical supervision architecture differs
Gallbladder-related events were reported by 2.5% on semaglutide 2.4 mg versus 1.6% on placebo, mainly gallstones (1.6% versus 1.1%)
Newer drugs like Mounjaro (Tirzepatide) combine GLP-1 and GIP (Glucose-Dependent Insulinotropic Peptide) effects